225Ac-DOTATOC-Targeted Somatostatin Receptor α-Therapy in a Patient With Metastatic Neuroendocrine Tumor of the Thymus, Refractory to β-Radiation

Somatostatin receptor-targeted alpha-therapy using alpha-emitter Ac-225-labeled somatostatin analogs has been suggested as a treatment option in advanced metastatic neuroendocrine tumors (NETs) failing treatment with beta-emitters, such as Lu-177 or Y-90. Thymus NETs are rare and usually more aggressive than other neuroendocrine tumor entities. We present here a case with beta-radiation refractory metastatic thymus NET, who demonstrated an excellent therapy response (molecular and morphological remission, as well as significantly improved clinical symptoms) after Ac-225-DOTATOC-targeted alpha-therapy, without any adverse effects during the treatment or in the follow-up period.

Automated summary

The case study presented a patient with beta-radiation refractory metastatic thymus NET who demonstrated excellent therapy response after Ac-225-DOTATOC-targeted alpha-therapy, showing molecular and morphological remission as well as significantly improved clinical symptoms, with no adverse effects observed during treatment or follow-up.